Preoperative Biological Therapy and Postoperative Outcomes Following Ileocolic Resection for Crohn's Disease.

Résumé fourni par la source

BACKGROUND: Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. Biological therapy has transformed disease management; however, its association with postoperative outcomes remains debated. OBJECTIVES: To evaluate the association between preoperative biological therapy and postoperative outcomes following ileocolic resection for Crohn's disease, and to identify additional factors associated with postoperative complications. METHODS: We conducted a single-center retrospective observational study of Crohn's disease patients who underwent ileocolic resection between 2021 and 2023. Patients were stratified according to preoperative exposure to biological therapy. RESULTS: Of 208 screened patients, 150 met inclusion criteria. Postoperative complications were more common in patients receiving biological therapy compared with controls (56% vs. 36.4%, P = 0.017), which was primarily driven by minor complications (48% vs. 30%, P = 0.022). Rates of major complications and length of hospital stay did not differ between the groups. Patients who developed major complications had significantly lower preoperative serum albumin levels (3.08 vs. 3.7 g/dl, P = 0.021). CONCLUSIONS: Preoperative biological therapy was associated with a higher rate of postoperative complications, predominantly minor in severity. Low preoperative serum albumin was associated with major postoperative complications, highlighting the importance of preoperative nutritional assessment and optimization.